Prohibition Partners Releases Global Medical Cannabis Market Review 2026

LONDON – With medical Cannabis exports increasingly concentrated among a small number of large-scale producers and patient markets advancing at different rates depending on local rules and access models, Prohibition Partners has released its Global Medical Cannabis Market Review 2026. The report maps the latest developments in cross-border supply flows, patient sector activity, and supply-chain adjustments across key countries.

The free to download analysis covers 2025 data and forward-looking snapshots for exporters and patient markets. It shows Canada shipped 275,343 kilograms of medical Cannabis last year, a figure that exceeded the combined total from every other exporting country and reflected more than 250% year-over-year growth. The report attributes the surge to Canada’s established domestic adult-use market, which supplies licensed producers with the scale and cost efficiencies that smaller cultivators elsewhere find difficult to match.

Germany recorded the strongest patient-market expansion outside North America. Its medical Cannabis sector reached an estimated $997 million in 2025, up 155% from the prior year. Regulatory moves that eased prescribing rules drove the increase, alongside the arrival of 35 cannabis-focused teleclinics – digital healthcare platforms offering 24/7 remote medical consultations, allowing patients to connect with doctors via smartphones or computers for diagnosis, prescriptions, and sick notes.

The United Kingdom followed a similar path. Market value climbed to $298 million, doubling from 2024 on 104% growth. Twenty-nine teleclinics now operate there, helping broaden patient access and supporting steady gains in prescriptions.

Telemedicine has become the main channel for patients in every sizable market the report examined. Australia counts 47 cannabis-specific teleclinics, Brazil 23. The model allows rapid onboarding but also concentrates prescribing power among a few large digital operators, a pattern the report tracks across four continents.

On the supply side, Portugal’s role has changed. Once viewed mainly as a cultivator, the country now functions as a processing and re-export hub. Official figures indicate it was likely a net importer of medical Cannabis by volume in 2025, even as it continued to ship finished products into European markets. The shift underscores how bulk imports, largely from Canada, feed downstream processing capacity in Europe.

The review also includes snapshots of patient markets in Australia, Poland, Israel, Brazil and France, plus exporter profiles for Denmark, North Macedonia, Spain, the Czech Republic, South Africa and Thailand. It examines how import quotas, domestic production levels and product availability interact in each jurisdiction.

The numbers confirm what many operators have sensed in recent quarters: growth remains concentrated in a handful of regulated patient markets, while global supply chains increasingly rely on a few efficient producers and specialized processors. The data will help companies test assumptions about sourcing, distribution margins, and patient acquisition costs as they set strategy for the rest of 2026 and beyond.